series-b
Stage
2026
Founded
3
Investors
About
T-Knife develops engineered T cell therapies targeting tumor antigens to treat solid tumors, including their lead candidate TK-6302 which targets PRAME for cancer treatment.
Explore T-Knife's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.